imatinib mesylate has been researched along with Neuroectodermal Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basso, G; Crescenzio, N; Ricotti, E; Rinaldi, A; Rosolen, A; Spinelli, M; Te Kronnie, G; Timeus, F | 1 |
1 other study(ies) available for imatinib mesylate and Neuroectodermal Tumors
| Article | Year |
|---|---|
Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Cell Transplantation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neuroblastoma; Neuroectodermal Tumors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reactive Oxygen Species; Sarcoma, Ewing; Time Factors; Transplantation, Heterologous; Tumor Burden | 2004 |